Currently Viewing:
COA 2017-ONCOLOGY PAYMENT REFORM
Currently Reading
Dr Roger Brito Discusses Practitioners Taking on 2-Sided Risk
February 12, 2018
Dr Peter Aran Discusses Year 1 Feedback on OCM
February 05, 2018
Dr Roger Brito on When Providers Should Be Involved in Reimbursement Model Development
January 31, 2018
Dr Mark Fendrick: How Expensive Therapies Fit Into VBID for Oncology
January 29, 2018
Bo Gamble Explains How COA Helps Practices Prepare for OCM
January 27, 2018
Dr Peter Aran on What Oncologists Implementing OCM Can Learn From Existing Models
January 24, 2018
Dr Roger Brito Discusses Implementing Alternative Payment Models and Its Challenges
January 20, 2018
Terrill Jordan Discusses the Process of Customizing an EMR to Adapt to OCM
January 19, 2018
Dr Mark Fendrick: Setting Cost-Sharing Based on Value, Not Price, in Cancer Care
January 18, 2018
David Merrill and John Robinson Discuss Barriers to APMs, Factors of Interest
January 15, 2018
Dr Jeff Patton Discusses Preparing for OCM, Seeing Improved Outcomes and Savings
January 12, 2018
Dr Peter Aran on Involving Providers in Development Process of New Reimbursement Models
January 11, 2018
Sarah Cevallos on Her Advice for Practices Looking to Participate in OCM
January 10, 2018
Dr Roger Brito: What Patients Should Know About Alternative Payment Models, OCM
January 09, 2018
Dr Mark Fendrick on Indication-Based Drug Pricing in Cancer Care
January 07, 2018
Bo Gamble on COA's Role in 2018
January 05, 2018
Judy Berger on What Southwest Airlines Is Doing in Oncology
January 04, 2018
Terrill Jordan Discusses Making Refinements in Year 2 of OCM
January 03, 2018
Sarah Cevallos: Physicians Need More Data to Determine if 2-Sided Risk is Appropriate
December 26, 2017

Dr Jeff Patton Highlights Challenges Encountered With Implementing OCM

Implementing OCM has presented several challenges, such as manually submitting data, keeping up with status of therapy, and billing, said Jeff Patton, MD, CEO of Tennessee Oncology.


Implementing the Oncology Care Model (OCM) has presented several challenges, such as manually submitting data, keeping up with status of therapy, and billing, said Jeff Patton, MD, CEO of Tennessee Oncology.

Transcript (slightly modified)

What challenges has your practice encountered with implementing OCM?

Reporting is very difficult, for us it’s basically manual. We just submitted our data and it took [full-time employees] 6 months to abstract the data, so that’s a challenge. Just keeping up with when folks are on therapy, off, when they go on and come off of an episode. Billing for orals is a challenge because sometimes those are filled elsewhere so we don’t know what the fill date is, and so how do you fill out a fill date when you don’t know?

I think another big challenge is with novel therapies. We do a lot of clinical research so our docs tend to adopt new technology, new therapies quicker, and in this program apparently that’s a bad thing. We think it’s a good thing, but we think we’re getting penalized for that. And then last, the lack of having real time data feedback on both quality measures and on the financial impact. You know, 18 months is a long time to wait for feedback.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!